BiotechTube
Home/Pipeline/VEGF Kinoid

VEGF Kinoid

Oncology (Solid Tumors)

PreclinicalInactive / Abandoned

Key Facts

Indication
Oncology (Solid Tumors)
Phase
Preclinical
Status
Inactive / Abandoned
Company
Neovacs

About Neovacs

Founded in 1993, Neovacs is a Paris-based biotech that historically focused on its innovative Kinoid® active immunotherapy platform, designed to induce a patient's own immune system to regulate harmful cytokines. Following a judicial reorganization in 2020, the company pivoted to a hybrid model, pairing the management of its legacy pipeline with strategic investments in external biotech and medtech companies. This strategy aims to leverage internal expertise for portfolio growth while seeking to revive its core R&D programs under improved financial conditions.

View full company profile

Therapeutic Areas

Autoimmune DiseasesAllergic Diseases

Other Oncology (Solid Tumors) Drugs

DrugCompanyPhase
OATD-02MolecurePhase I
ANXVAnnexin PharmaceuticalsPreclinical
Athebody® DARPins for Targeted Radioligands (with POINT Biopharma)AthebioPre-clinical
AB821Asher BiotherapeuticsPreclinical
Undisclosed Preclinical PipelineOncoResponsePreclinical
Undisclosed Platform ProgramDa Zen TheranosticsPre-clinical
Compound42Abbmira TherapeuticsPre-clinical
Clinical Decision Support ServiceCurematchCommercial
CV6-168CV6 TherapeuticsPhase 1a
Chemophototherapy (CPT)POP BiotechnologiesPre-clinical
HRD Testing SolutionSeqOne GenomicsCommercial
Platform Validation & Partnership DevelopmentSingleCell BiotechnologyPre-clinical